<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the treatment of chronic myeloid leukemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the treatment of chronic myeloid leukemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the treatment of chronic myeloid leukemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles A Schiffer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ehab Atallah, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic myeloid leukemia (CML; previously called chronic myelogenous leukemia) is a myeloproliferative neoplasm (MPN), in which cells of the granulocytic lineage are the predominant proliferative component. CML is associated with the Philadelphia chromosome, t(9;22)(q34;q11), which creates a
         <em>
          BCR::ABL1
         </em>
         fusion gene  (
         <a class="graphic graphic_figure graphicRef62227" href="/z/d/graphic/62227.html" rel="external">
          figure 1
         </a>
         ). This genetic abnormality encodes the constitutively active tyrosine kinase BCR::ABL1, which is essential to the development of CML and is the primary target for treatment of CML.
        </p>
        <p>
         CML shares the following biologic features with the other MPNs, namely, polycythemia vera, essential thrombocythemia, and primary myelofibrosis  (
         <a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">
          "Overview of the myeloproliferative neoplasms"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stem cell origin
         </strong>
         – Clonal disorders that arise in a hematopoietic stem or early progenitor cell
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysregulated proliferation
         </strong>
         – Dysregulated production of a particular lineage of mature myeloid cells with fairly normal differentiation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progression to acute leukemia
         </strong>
         – Variable rates of progression to acute leukemia
        </p>
        <p>
        </p>
        <p>
         An overview of treatment of CML is presented in this topic.
        </p>
        <p>
         Clinical presentation, diagnosis, and initial treatment of CML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3743119908">
         <span class="h1">
          DISEASE PHASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for CML and its disease phases are evolving [
         <a href="#rid1">
          1-3
         </a>
         ]. The natural history of CML has been traditionally described as triphasic; however, some experts now view CML as biphasic process:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic phase
         </strong>
         <strong>
          (CP)
         </strong>
         – The most common clinical presentation of CML is CP, which is manifest as leukocytosis (with neutrophils in various stages of maturation), hypercellular bone marrow with marked granulocytic proliferation and few blasts (eg, &lt;5 percent), with or without splenomegaly. CP CML is a relatively indolent disorder that is easily controlled with oral agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advanced disease (accelerated phase [AP]
         </strong>
         <strong>
          and/or
         </strong>
         <strong>
          blast phase [BP])
         </strong>
         – Together, AP and BP may be considered as a continuum of more aggressive CML. Advanced CML most often arises during treatment of CP CML. AP and BP are uncommon initial presentations of CML, but this is more likely in settings of limited access to medical care where diagnosis may be delayed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advanced disease is characterized by increasing blood/marrow blasts (AP: 10 to 19 percent; BP: ≥20 percent) and/or extramedullary collections of blasts. This is often accompanied by increasing splenomegaly, constitutional symptoms, worsening cytopenias, and/or genetic instability (eg, additional chromosomal abnormalities). Advanced disease may manifest as an acute leukemia, which can resemble acute myeloid leukemia (AML) or, less often, acute lymphoblastic leukemia. Compared with CP CML, advanced CML is considerably more difficult to control.
        </p>
        <p>
        </p>
        <p>
         Evolving diagnostic criteria should be kept in mind when reviewing treatment outcomes. Diagnostic criteria for CML and its phases are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML disease phase, prognostic score, and comorbid conditions should be determined before initiating treatment.
        </p>
        <p class="headingAnchor" id="H2348367968">
         <span class="h2">
          Clinical/laboratory
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical evaluation should assess comorbidities (eg, cardiovascular, pulmonary, kidney, pancreatic, or liver disease and diabetes) that may influence the choice of initial therapy and medications that may interact with tyrosine kinase inhibitors (TKIs)  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         In addition to history and physical examination, the following studies should be obtained:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematology
         </strong>
         – Complete blood count (CBC) with differential count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum chemistries
         </strong>
         – Electrolytes, glucose, liver function tests, kidney function tests, uric acid.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetic and molecular testing
         </strong>
         – Cytogenetic and molecular testing of marrow or blood:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytogenetics
         </strong>
         – Chromosome banding to confirm detection of the t(9;22) (Philadelphia chromosome [Ph]) rearrangement and to identify additional chromosomal abnormalities (ACA).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Polymerase chain reaction (PCR)
         </strong>
         – Quantitative PCR to establish a baseline value for
         <em>
          BCR::ABL1
         </em>
         rearrangement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral testing
         </strong>
         – Hepatitis B panel; there are rare cases of hepatitis B reactivation with treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrocardiogram (EKG)
         </strong>
         – Assess arrhythmias and QT interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiography
         </strong>
         – Pleural effusions or parenchymal disease.
        </p>
        <p>
        </p>
        <p>
         Diagnostic criteria for CML and discussion of pretreatment evaluation are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6645549">
         <span class="h2">
          Prognostic score
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML prognosis is estimated using one of the validated CML clinical scoring systems.
        </p>
        <p>
         We favor the ELTS (EUTOS Long Term Survival) score, which is based on data from tyrosine kinase inhibitor (TKI)-treated patients (rather than non-TKI-based management) and uses simple hematologic data, spleen size, and age [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         Validated CML clinical scoring systems  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ) are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ELTS (EUTOS Long Term Survival) score (
         <a class="calc calc_professional" href="/z/d/html/127093.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sokal (
         <a class="calc calc_professional" href="/z/d/html/16342.html" rel="external">
          calculator 2
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Euro (Hasford) [
         <a href="#rid7">
          7
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EUTOS (online calculator [
         <a href="#rid8">
          8
         </a>
         ]) [
         <a href="#rid9">
          9
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Details of CML prognostic models are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TREATMENT OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML is associated with the Philadelphia chromosome (Ph), which refers to the t(9;22)(q34;q11) chromosomal translocation. This rearrangement creates
         <em>
         </em>
         a
         <em>
          BCR::ABL1
         </em>
         gene fusion, which encodes the constitutively active tyrosine kinase, BCR::ABL1. Because of the essential role of this genetic rearrangement in the generation and maintenance of CML, BCR::ABL1 tyrosine kinase inhibitors (TKIs) play an important role in management of all phases of CML.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of care
         </strong>
         – The goals of care for patients with CML are to achieve clinical, cytogenetic, and molecular remission; maintain long-term disease control; and avoid progression to advanced disease (ie, accelerated phase [AP] or blast phase [BP]), while optimizing quality of life by limiting treatment-related toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many patients and clinicians also consider achieving a treatment-free remission (TFR) an important goal. (See
         <a class="local">
          'TKI discontinuation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Palliation of symptoms may be the goal for severely debilitated or frail patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatments
         </strong>
         – Patients are treated with a BCR::ABL1 TKI, unless there is a specific contraindication. Selection of a TKI is influenced by disease phase and comorbid conditions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tyrosine kinase inhibitors
         </strong>
         – TKIs are oral agents that are the preferred treatment for almost all newly-diagnosed patients with CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Selection of a TKI is guided by disease phase, CML risk score, adverse effects (AEs), and comorbid conditions. For patients with advanced disease, selection of a TKI is also influenced
         <em>
         </em>
         by
         <em>
          BCR::ABL1
         </em>
         mutations. (See
         <a class="local">
          'Initial treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Individual TKIs are discussed below. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other agents
         </strong>
         – Other medications can provide symptomatic relief for patients who cannot take a TKI (eg, pregnancy), who have intolerance/severe AEs with multiple TKIs, or who require additional symptomatic relief. Examples of other agents include interferon alfa,
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , and/or cytotoxic agents (eg,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         ). (See
         <a class="local">
          'Other agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Allogeneic hematopoietic cell transplantation (HCT)
         </strong>
         – Allogeneic HCT refers to treatment with intensive chemotherapy and/or radiation therapy to reduce the burden of CML cells, followed by restoration of blood cell formation by infusion of hematopoietic stem/progenitor cells from another individual (donor). Allogeneic HCT can cure some patients with CML (with outcomes related to the phase of disease at transplantation), but it is associated with substantial short-term and long-term toxicity (including graft-versus-host disease [GVHD] and second cancers) and treatment-related mortality. HCT is reserved for patients with advanced disease. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         BCR::ABL1 tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for all phases of CML and are used for initial treatment, unless there is a specific contraindication (eg, pregnancy).
        </p>
        <p>
         The development of TKIs has been one of the most exhilarating stories in modern medicine. With the elucidation of BCR::ABL1 as the key molecular defect in CML came a more complete understanding of the underlying pathophysiology, culminating in development of these highly effective agents.
        </p>
        <p>
         Initial treatment of CML is stratified according to disease phase (ie, chronic phase versus advanced disease) and prognostic score (ie, low/intermediate-risk versus high-risk), as described in the sections that follow.
        </p>
        <p>
         Initial treatment of CML generally uses either
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or a second-generation (2G) TKI (ie,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ). Other TKIs (ie,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         ) are reserved for patients who have demonstrated resistance to other TKIs or with specific
         <em>
          BCR::ABL1
         </em>
         mutations (eg, T315I). (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p>
         Monitoring the response to TKI treatment is discussed below. (See
         <a class="local">
          'Monitoring response'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Chronic phase (CP)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with CP CML, we stratify selection of a BCR::ABL1 TKI according to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognostic score
         </strong>
         – CML risk score (ie, low/intermediate-risk versus high-risk)  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other considerations
         </strong>
         – Toxicity profile, comorbid illnesses, medications that may interact with TKIs  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ), availability, cost, patient preference, and the weight the patient places on achieving a treatment-free remission (TFR).
        </p>
        <p>
        </p>
        <p>
         All BCR::ABL1 TKIs are effective for initial treatment of CP CML. There is no significant difference in overall survival (OS) between patients who begin treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         versus a 2G TKI (eg,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ). However, compared with imatinib, 2G TKIs generally achieve faster and deeper remissions and have lower rates of progression to advanced phase CML.
        </p>
        <p>
         Administration, adverse effects (AEs), and outcomes of individual TKIs are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         can provide urgent relief for some patients with extreme leukocytosis (eg, &gt;100,000/microL) or who are severely symptomatic with splenomegaly or systemic symptoms [
         <a href="#rid10">
          10
         </a>
         ]. Occasional patients are not candidates for treatment with a TKI (eg, initial diagnosis during pregnancy, due to potential teratogenicity). (See
         <a class="local">
          'Other agents'
         </a>
         below.)
        </p>
        <p>
         Detailed discussion of management of CP CML is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3333633746">
         <span class="h3">
          Low/intermediate-risk CP CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with low-risk or intermediate-risk CP CML  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ), the choice of a TKI is influenced by the importance assigned to achievement of a TFR:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TFR is an important goal
         </strong>
         – For patients who consider TFR an important goal, we generally treat with a 2G TKI, rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , based on faster, deeper remissions and lower rates of progression to advanced phase CML. Nevertheless, no studies have directly demonstrated greater success in achieving TFR using a 2G TKI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selection of a 2G TKI should consider the toxicity profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 5
         </a>
         ), comorbid conditions, availability, cost, and patient preference. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Less importance assigned to TFR
         </strong>
         – For patients who do not consider TFR a high priority, treatment with either
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or a 2G TKI is acceptable. The choice of TKI for initial treatment is based on toxicity profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 5
         </a>
         ), comorbid conditions, availability, cost, and patient preference. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4220140577">
         <span class="h3">
          High-risk score CP CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with high-risk score CP CML  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ), we favor initial treatment with a 2G TKI (ie,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         because 2G TKIs are associated with a lower risk of progression to advanced disease (ie, accelerated phase [AP] or blast phase [BP]) CML.
        </p>
        <p>
         None of the individual 2G TKIs has proven to be superior in this setting. Selection of a 2G TKI should consider the toxicity profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 5
         </a>
         ), comorbid conditions, availability, cost, and patient preference. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Advanced disease (accelerated phase/blast phase
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat patients with advanced disease using a 2G TKI,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ; selection of a specific TKI is guided by mutation analysis of
         <em>
          BCR::ABL1
         </em>
         , toxicity profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 5
         </a>
         ), and comorbidities. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         below.)
        </p>
        <p>
         Patients with myeloid blast phase CML may also need cytotoxic chemotherapy, using regimens similar to those for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), together with a TKI.
        </p>
        <p>
         We initiate a search for a human leukocyte antigen (HLA)-matched donor at the time of diagnosis of advanced CML. A decision to proceed to allogeneic hematopoietic cell transplantation (HCT) is guided by the response to TKI therapy, medical fitness, and availability of a suitable donor. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          MONITORING RESPONSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to tyrosine kinase inhibitor (TKI) therapy must be monitored on a regular schedule.
        </p>
        <p class="headingAnchor" id="H661135">
         <span class="h2">
          Schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to initial therapy is assessed according to hematologic, cytogenetic, and molecular criteria.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematology
         </strong>
         – Monitor complete blood count (CBC) with differential every one to two weeks until a complete hematologic response (CHR)  (
         <a class="graphic graphic_table graphicRef52082" href="/z/d/graphic/52082.html" rel="external">
          table 6
         </a>
         ) is achieved, then repeat at times of cytogenetic or molecular testing, or as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CHR is described below. (See
         <a class="local">
          'Response milestones'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – Monitoring the karyotype is used primarily for patients with atypical translocations (ie, rare or atypical
         <em>
          BCR::ABL1
         </em>
         transcripts that cannot be measured by quantitative polymerase chain reaction [PCR]), treatment failure or resistance (ie, to exclude additional chromosomal abnormalities), and with progression to advanced disease (ie, accelerated phase [AP] or blast phase [BP]). Fluorescence in situ hybridization (FISH) may be helpful for monitoring response in patients with atypical transcripts, but chromosome banding is needed for detection of additional chromosomal translocations. Note that monitoring the karyotype alone (ie, without molecular analysis) is not sufficiently sensitive to monitor response for most patients with CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Descriptions of cytogenetic response are provided below  (
         <a class="graphic graphic_table graphicRef52082" href="/z/d/graphic/52082.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Response milestones'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reverse transcriptase
         </strong>
         <strong>
          polymerase chain reaction (RT-PCR)
         </strong>
         – Monitor quantitative RT-PCR of blood every three months until achievement of major molecular response (MMR; ie, 3 log reduction of
         <em>
          BCR::ABL1
         </em>
         ). Subsequent testing is performed every three to six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Descriptions of molecular response are provided below. (See
         <a class="local">
          'Response milestones'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Continued testing after MMR is important to assess eligibility for treatment discontinuation. (See
         <a class="local">
          'TKI discontinuation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3433382702">
         <span class="h2">
          Response criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to TKI therapy  (
         <a class="graphic graphic_table graphicRef52082" href="/z/d/graphic/52082.html" rel="external">
          table 6
         </a>
         ) is defined according to European LeukemiaNet guidelines [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H440188727">
         <span class="h3">
          Hematologic response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete hematologic response (CHR) is defined as [
         <a href="#rid11">
          11,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White blood cell count (WBC) &lt;10,000/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No circulating immature myeloid cells and &lt;5 percent basophils
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelet count &lt;450,000/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spleen not palpable
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1086421755">
         <span class="h3">
          Cytogenetic response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytogenetic response is assessed by chromosome banding of marrow metaphases with ≥20 metaphases analyzed. Chromosome banding generally requires a bone marrow aspirate sample.
        </p>
        <p>
         Cytogenetic response is classified according to the percentage of Philadelphia chromosome positive (Ph+) cells  (
         <a class="graphic graphic_table graphicRef52082" href="/z/d/graphic/52082.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid11">
          11,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No cytogenetic response
         </strong>
         – &gt;95 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal
         </strong>
         <strong>
          cytogenetic response
         </strong>
         – 66 to 95 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minor
         </strong>
         <strong>
          cytogenetic response
         </strong>
         – 36 to 65 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Major
         </strong>
         <strong>
          cytogenetic response
         </strong>
         – 1 to 35 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete
         </strong>
         <strong>
          cytogenetic response (CCyR)
         </strong>
         – No Ph+ cells
        </p>
        <p>
        </p>
        <p>
         For patients with an inadequate number of metaphases, CCyR can also be documented by FISH of blood interphase cell nuclei that demonstrate &lt;1 percent
         <em>
          BCR::ABL1
         </em>
         -positive nuclei among ≥200 nuclei [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1987348817">
         <span class="h3">
          Molecular response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Molecular response is determined according to the International Scale (IS) as the ratio of
         <em>
          BCR::ABL1
         </em>
         transcripts to
         <em>
          ABL1
         </em>
         transcripts (or other housekeeping genes) and is expressed as
         <em>
          BCR::ABL1
         </em>
         percentage, on a log scale [
         <a href="#rid11">
          11
         </a>
         ]. Results are presented as log reduction of
         <em>
          BCR::ABL1
         </em>
         /
         <em>
          ABL1
         </em>
         compared to a standardized baseline, which is defined as 100 percent (note that molecular response is not compared with the patient's own baseline value):
        </p>
        <p>
         Key molecular response milestones are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MR 3 (Major molecular response [MMR])
         </strong>
         – 0.1 percent of baseline
         <em>
          BCR::ABL1
         </em>
         /
         <em>
          ABL1
         </em>
         (ie, ≥3 log reduction)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MR 4
         </strong>
         – 0.01 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MR 4.5
         </strong>
         – 0.0032 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MR 5
         </strong>
         – 0.001 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1006091634">
         <span class="h2">
          Response milestones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Milestones for molecular response to therapy are used to determine if the current treatment should be continued (ie, Optimal response), changed (ie, Failure/resistance), or considered for continuation (ie, Warning) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Molecular milestones of
         <em>
          BCR::ABL1
         </em>
         transcript levels are assessed at 3, 6, and 12 months. Additional testing may be needed if the response kinetics are uncertain or if toxicity/intolerance causes treatment interruptions or dose reductions.
        </p>
        <p>
         In most circumstances, changes in a single PCR result alone should not be used to define treatment failure. However, a pattern of increasing PCR signal, with or without hematologic or cytogenetic evidence of failure, should trigger
         <em>
          BCR::ABL1
         </em>
         mutational analysis [
         <a href="#rid11">
          11,14-16
         </a>
         ]. (See
         <a class="local">
          'Evaluation at loss of response'
         </a>
         below.)
        </p>
        <p>
         The following definitions apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          3 months
         </strong>
         – Optimal (≤10 percent); Warning (&gt;10 percent); Failure (&gt;10 percent, if confirmed within 1 to 3 months)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6 months
         </strong>
         – Optimal (≤1 percent); Warning (&gt;1 to 10 percent); Failure &gt;10 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          12
         </strong>
         <strong>
          months
         </strong>
         – Optimal (≤0.1 percent); Warning (&gt;0.1 to 1 percent); Failure &gt;1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Any time
         </strong>
         – Optimal (≤0.1 percent); Warning (&gt;0.1 to 1 percent, with loss of MMR [ie, ≤0.1 percent]); Failure &gt;1 percent, resistance mutations, or acquisition of additional chromosomal abnormalities
        </p>
        <p>
        </p>
        <p>
         Achieving MMR (ie,
         <em>
          BCR::ABL1
         </em>
         ≤0.1 percent) within one year predicts a CML-specific survival close to 100 percent [
         <a href="#rid11">
          11
         </a>
         ]. Prospective and retrospective studies that support use of milestone criteria for managing CML are presented separately [
         <a href="#rid17">
          17-27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1625190445">
         <span class="h1">
          TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H2994360752">
         <span class="h2">
          Tyrosine kinase inhibitors (TKI)
         </span>
         <span class="headingEndMark">
          —
         </span>
         TKIs are effective oral agents that target the BCR::ABL1 tyrosine kinase.
        </p>
        <p>
         Selection of a TKI is guided by disease phase (ie, chronic phase [CP] versus advanced disease) and CML risk score (ie, low/intermediate-risk versus high-risk)  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ). Other considerations include side effect profile, comorbid illnesses, medications that may interact with TKIs  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ), availability, cost, patient preference/convenience, and importance assigned by a patient to achieving a treatment-free remission (TFR). (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
         All TKIs are associated with common, generally mild toxicities (eg, rash, nausea, edema, fatigue, myalgias/arthralgias) in the first months of treatment; most resolve spontaneously or can be controlled by dose adjustments. Management of these early adverse effects (AEs) is discussed separately. Interruption of TKI therapy has been associated with poor long-term outcomes. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Managing toxicity'
         </a>
         .)
        </p>
        <p>
         In addition, each TKI is associated with particular AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 5
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         – Muscle cramps, fatigue, edema, nausea, diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nilotinib
         </strong>
         – Coronary, cerebral, and peripheral vascular disease; prolonged QTc interval; hyperglycemia; pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         – Pleural or pericardial effusion, pulmonary hypertension, prolonged QTc interval, platelet dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bosutinib
         </strong>
         – Diarrhea, abnormal liver function, rash, pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         – Arterial and venous thrombosis, embolic events, liver toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asciminib
         </strong>
         – Pancreatitis, upper respiratory tract infection, musculoskeletal pain.
        </p>
        <p>
        </p>
        <p>
         As examples of how we consider comorbidities and AEs in selecting a TKI for initial treatment of CML:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart disease or hyperglycemia
         </strong>
         – For patients with arrhythmias, coronary artery disease, or hyperglycemia, we favor
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreatitis
         </strong>
         – For patients with a history of pancreatitis we favor
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung disease
         </strong>
         – For patients with a history of lung disease or at risk for pleural effusion, we favor
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Detailed discussion of selecting a TKI for initial treatment of CML is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Choosing a TKI'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , and radotinib have been tested against
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         in randomized, company-sponsored trials, but they have not been tested against each other. Comparisons among these and other clinical studies are difficult because of differences in protocols and methods of evaluation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         are approved for initial treatment of CML by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA); radotinib has been approved in South Korea only.
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          Asciminib
         </a>
         is approved for patients with CP CML previously treated with ≥2 TKIs or with T315I mutation.
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is approved for patients with CP CML with resistance or intolerance to ≥2 prior TKIs, advanced phase CML for which no other TKIs are indicated, and for patients with T315I-positive CML (CP or advanced disease).
        </p>
        <p class="headingAnchor" id="H951290964">
         <span class="h2">
          Other agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other drugs can be used for treatment of CML in certain settings. None of these agents approaches the efficacy of TKIs, but they may be used when TKIs cannot be given safely (eg, pregnancy), to relieve symptoms or prevent complications while awaiting results of mutation analysis, or for managing TKI resistance.
        </p>
        <p>
         Examples of settings in which non-TKI agents might be used include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydroxyurea
         </strong>
         – A short course of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (eg, 20 to 40 mg/kg/day, adjusted up or down to the nearest pill) [
         <a href="#rid10">
          10
         </a>
         ] may be given to patients with significant leukocytosis (eg, &gt;100,000/microL), systemic symptoms, or symptomatic splenomegaly while awaiting results from cytogenetic or molecular confirmation of the diagnosis of CML or for management of advanced phase CML while awaiting
         <em>
          BCR::ABL1
         </em>
         mutation analysis. The dose should be tapered as the white blood cell count decreases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interferon
         </strong>
         – Interferon (IFN) alfa can be given to patients who are diagnosed with CML during pregnancy. TKIs are contraindicated in women who seek to become pregnant and in the first trimester of pregnancy because of increased rates of miscarriage and fetal abnormalities. IFN alfa is considered safe during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Omacetaxine
         </strong>
         <strong>
          mepesuccinate
         </strong>
         – This agent, previously known as homoharringtonine, can be used for treatment of resistance and/or intolerance to ≥2 TKIs.
        </p>
        <p>
        </p>
        <p>
         These and other agents (eg,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         ) are mostly of historic interest, although they can benefit patients who are not candidates for transplantation and are intolerant of or refractory to treatment with TKIs.
        </p>
        <p class="headingAnchor" id="H2503074772">
         <span class="h2">
          Hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option for medically-fit patients with advanced disease (ie, accelerated phase [AP]/blast phase [BP]). HCT is occasionally offered for younger patients with chronic phase (CP) CML who have a suitable donor and are not responding adequately to TKI therapy. However, HCT is associated with significant early and late toxicity and an increased rate of early mortality.
        </p>
        <p>
         A decision to proceed to allogeneic HCT must consider:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medically eligible
         </strong>
         – Eligibility for transplantation, based on age (eg, &lt;70 years in many institutions) and medical fitness. (See
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suitable donor
         </strong>
         – Donors may include a human leukocyte antigen (HLA)-matched related or unrelated donor, haploidentical related donor, or umbilical cord blood.
        </p>
        <p>
        </p>
        <p>
         Selection of a donor, method for graft collection, and choice of a conditioning (preparative) regimen are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1003008342">
         <span class="h1">
          TKI DISCONTINUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with a tyrosine kinase inhibitor (TKI) is generally continued indefinitely, as long as the drug is tolerated and treatment milestones are met. However, patients with a sustained, deep molecular response may seek TKI discontinuation because of toxicity, convenience, cost, a desire to become pregnant, or other reasons.
        </p>
        <p>
         TKI discontinuation should take place only after meeting all criteria for treatment discontinuation including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reliable use of the TKI for ≥3 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No prior resistance to a second-generation (2G) TKI that required switching to another agent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stable molecular response on repeated testing (ie, MR4;
         <em>
          BCR-ABL1
         </em>
         ≤0.01 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Access to a reliable quantitative polymerase chain reaction (PCR) test that can detect at least MR 4.5 and can provide results within two weeks
        </p>
        <p>
        </p>
        <p>
         Details of criteria for treatment discontinuation, adverse effects of discontinuation, and outcomes are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'TKI discontinuation for TFR'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1289633135">
         <span class="h1">
          DISEASE RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who appear to have resistant disease should be questioned carefully to assure that they are taking the tyrosine kinase inhibitor (TKI) at the recommended dose and schedule and avoiding medications or herbal supplements that may impair efficacy  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Management of adverse effects of TKIs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Managing toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H272446834">
         <span class="h2">
          Evaluation at loss of response
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are reliably taking the TKI, yet do not achieve molecular milestones (ie, "Failure" or "Warning"), disease status must be re-evaluated. Response milestones are discussed above. (See
         <a class="local">
          'Response milestones'
         </a>
         above.)
        </p>
        <p>
         For patients with suspected TKI resistance, testing includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematology
         </strong>
         – Complete blood count with differential count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow examination
         </strong>
         – Including microscopy and cytogenetic testing to evaluate progression to advanced disease (ie, accelerated phase [AP] or blast phase [BP])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mutation status
         </strong>
         –
         <em>
          ABL1
         </em>
         kinase domain (KD) mutation analysis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Treatment of disease resistance or drug intolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance to a TKI is usually detected when a patient with an initial response to a TKI loses that response. Approximately 40 to 50 percent of patients change from their initial TKI due to resistance or intolerance [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Management of TKI resistance is guided by
         <em>
          ABL1
         </em>
         KD mutation analysis.
        </p>
        <p>
         The more common acquired
         <em>
          ABL1
         </em>
         KD mutations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T315I
         </strong>
         – Resistant to all TKIs, except
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Y253F
         </strong>
         and
         <strong>
          F359V
         </strong>
         – Sensitive to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , but resistant to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          E255V
         </strong>
         – Sensitive to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , but resistant to
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          F317L
         </strong>
         – Sensitive to
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , but resistant to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          V299L
         </strong>
         – Sensitive to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , but resistant to
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87038" href="/z/d/drug information/87038.html" rel="external">
          Omacetaxine
         </a>
         mepesuccinate (previously known as homoharringtonine) may also be considered for treatment of TKI resistance.
        </p>
        <p>
         Drug selection for treatment of TKI resistance is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
         Allogeneic hematopoietic cell transplantation (HCT) is an option for patients who progress to advanced disease (ie, accelerated phase or blast phase) who are resistant to multiple TKIs or are unable to tolerate a TKI . (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H83965509">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117207.html" rel="external">
          "Society guideline links: Chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H992092">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15792.html" rel="external">
          "Patient education: Chronic myeloid leukemia (CML) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/684.html" rel="external">
          "Patient education: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">
          "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the Philadelphia chromosome, t(9;22)(q34;q11), which creates a
         <em>
          BCR::ABL1
         </em>
         fusion gene  (
         <a class="graphic graphic_figure graphicRef62227" href="/z/d/graphic/62227.html" rel="external">
          figure 1
         </a>
         ) and the constitutively active tyrosine kinase, BCR::ABL1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease phases
         </strong>
         – Diagnostic criteria for disease phases of CML are evolving. Briefly, CML disease phases can be described as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic phase
         </strong>
         <strong>
          (CP)
         </strong>
         – A relatively indolent condition with leukocytosis (that includes various stages of neutrophil maturation), hypercellular marrow, few blasts, with or without splenomegaly. CP CML is readily controlled with oral agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Advanced disease
         </strong>
         – Accelerated phase (AP) and blast phase (BP) can be considered a continuum of more aggressive CML that is unusual at initial presentation but arises more often during treatment of CP CML. Advanced disease is generally manifest with increasing blasts, splenomegaly, constitutional symptoms, worsening cytopenias, and/or genetic instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Includes comorbid conditions (eg, heart, lung, kidney diseases), CML phase, and prognostic score.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – BCR::ABL1 tyrosine kinase inhibitors (TKI) are the initial treatment of CML, unless contraindicated (eg, pregnancy). TKI choice is stratified by disease phase (ie, chronic phase versus advanced disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of CP
         </strong>
         – Choice of TKI is based on CML risk score  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ), toxicity, comorbidities, availability, cost, and patient preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low/intermediate risk
         </strong>
         – Stratified by importance of achieving treatment-free remission (TFR) (see
         <a class="local">
          'Low/intermediate-risk CP CML'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          TFR is an important goal
         </strong>
         – For patients who consider TFR an important goal, we generally treat with a second generation (2G) TKI (eg,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ), rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          TFR is less important
         </strong>
         – If a TFR is not a high priority, treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or a 2G TKI is acceptable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – We favor initial treatment with a 2G TKI, rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         .
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         should be given if
         <em>
          BCR::ABL1
         </em>
         T315I mutation is present. (See
         <a class="local">
          'High-risk score CP CML'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of advanced disease
         </strong>
         – We favor treatment with a 2G TKI,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ; selection of a TKI is based on mutation analysis, toxicities, and comorbidities. (See
         <a class="local">
          'Advanced disease (accelerated phase/blast phase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response
         </strong>
         – The schedule for monitoring hematologic, cytogenetic, and molecular responses and various treatment milestones are discussed above. (See
         <a class="local">
          'Monitoring response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TKIs
         </strong>
         – TKI selection is guided by disease phase, CML risk score  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 4
         </a>
         ), side effect profile, comorbid illnesses, availability, cost, and patient preferences. (See
         <a class="local">
          'Tyrosine kinase inhibitors (TKI)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other treatments
         </strong>
         –
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         , interferons, and other agents are used occasionally. (See
         <a class="local">
          'Other agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transplantation
         </strong>
         – Allogeneic hematopoietic cell transplantation is a consideration for medically-fit patients with a suitable donor who have advanced disease or intolerance/resistance to all TKIs. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TKI discontinuation
         </strong>
         – Selected patients who achieve a sustained, deep remission may be candidates for TKI discontinuation, as discussed above. (See
         <a class="local">
          'TKI discontinuation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease resistance
         </strong>
         – For patients who are taking the TKI properly, evaluation for disease progression or emergence of
         <em>
          BCR::ABL1
         </em>
         mutation resistance and selection of an alternative TKI or other treatment is discussed above. (See
         <a class="local">
          'Disease resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1039937955">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert S Negrin, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia 2020; 34:2138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850.
          </a>
         </li>
         <li class="breakAll">
          Online calculation of the EUTOS Score. ELN-Foundation. Available at: https://www.leukemia-net.org/content/leukemias/cml/eutos_score/index_eng.html (Accessed on August 04, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012; 120:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009; 114:4939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009; 145:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branford S, Yeung DT, Prime JA, et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 2012; 119:4264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112:4437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009; 115:3709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118:4541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116:3758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121:4867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilhot J, Preudhomme C, Mahon FX, Guilhot F. Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer 2015; 121:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4496 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26416462" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32601376" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6584184" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prognostic discrimination in "good-risk" chronic granulocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625174" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625174" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536864" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22613793" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : How I treat newly diagnosed chronic phase CML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32127639" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803709" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797518" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19344397" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21562040" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431575" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18716134" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19517462" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21803854" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679528" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22067393" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23620574" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297946" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859364" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prognosis for patients with CML and&gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311723" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335106" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28273028" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25346428" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637609" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
